CL2021000153A1 - Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 - Google Patents
Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1Info
- Publication number
- CL2021000153A1 CL2021000153A1 CL2021000153A CL2021000153A CL2021000153A1 CL 2021000153 A1 CL2021000153 A1 CL 2021000153A1 CL 2021000153 A CL2021000153 A CL 2021000153A CL 2021000153 A CL2021000153 A CL 2021000153A CL 2021000153 A1 CL2021000153 A1 CL 2021000153A1
- Authority
- CL
- Chile
- Prior art keywords
- interleukin
- inhibitors
- activity
- compounds
- sulfonimidamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000153A1 true CL2021000153A1 (es) | 2021-07-09 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000153A CL2021000153A1 (es) | 2018-07-20 | 2021-01-19 | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12234245B2 (enExample) |
| EP (1) | EP3823974A1 (enExample) |
| JP (1) | JP7320595B2 (enExample) |
| KR (1) | KR20210034596A (enExample) |
| CN (1) | CN112513048A (enExample) |
| AR (1) | AR115822A1 (enExample) |
| AU (1) | AU2019306658A1 (enExample) |
| BR (1) | BR112021001044A2 (enExample) |
| CA (1) | CA3105521A1 (enExample) |
| CL (1) | CL2021000153A1 (enExample) |
| CO (1) | CO2021001530A2 (enExample) |
| CR (1) | CR20210022A (enExample) |
| IL (1) | IL279256A (enExample) |
| MA (1) | MA53172A (enExample) |
| MX (1) | MX2021000780A (enExample) |
| PE (1) | PE20211811A1 (enExample) |
| PH (1) | PH12021500005A1 (enExample) |
| SG (1) | SG11202013062VA (enExample) |
| TW (1) | TWI825134B (enExample) |
| UA (1) | UA128558C2 (enExample) |
| WO (1) | WO2020018975A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| CN113015730A (zh) | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113166081A (zh) | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| JP2022518260A (ja) * | 2019-01-23 | 2022-03-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3158123A1 (en) * | 2019-11-12 | 2021-05-20 | Yonggang Wei | Amide derivative and preparation method therefore and use thereof in medicine |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CA3175729A1 (en) * | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3174837A1 (en) | 2020-04-15 | 2021-10-21 | Daniel Oehlrich | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| EP4135842B1 (en) | 2020-04-15 | 2024-10-23 | JANSSEN Pharmaceutica NV | Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| KR20230016658A (ko) | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| KR20230152016A (ko) | 2021-03-04 | 2023-11-02 | 얀센 파마슈티카 엔브이 | Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체 |
| CA3208414A1 (en) | 2021-03-04 | 2022-09-09 | Daniel Oehlrich | 4-amino-6-oxo-pyridazine derivatives modulating nlrp3 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| TW202246230A (zh) * | 2021-05-10 | 2022-12-01 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| CN116917282B (zh) * | 2021-05-10 | 2026-08-11 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| AR126474A1 (es) * | 2021-07-19 | 2023-10-11 | Genentech Inc | Compuestos de sulfonimidamida y uso de los mismos |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| JP2025502732A (ja) | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| US20250388568A1 (en) * | 2022-07-06 | 2025-12-25 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| CN119907797A (zh) | 2022-09-23 | 2025-04-29 | 默沙东有限责任公司 | 用作nod样受体蛋白3抑制剂的酞嗪衍生物 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025101716A1 (en) * | 2023-11-07 | 2025-05-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of trifunctionalized sulfur(vi) compounds |
| US20250223290A1 (en) | 2023-12-14 | 2025-07-10 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| TW202535370A (zh) | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| CN122555708A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| CN122555707A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2025222076A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases |
| CN119100956B (zh) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705555A (en) * | 1984-08-08 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Herbicidal triazines |
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DK1270565T3 (da) | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| BR0014003A (pt) | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| CA2789665C (en) | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| TW201311693A (zh) | 2011-09-02 | 2013-03-16 | Kyowa Hakko Kirin Co Ltd | 化學激活激素受體活性調節劑 |
| WO2014190015A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐモジュレータ |
| JP2021529780A (ja) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CR20210235A (es) | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113166081A (zh) | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113286784A (zh) | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| JP2022518260A (ja) | 2019-01-23 | 2022-03-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| IL295120A (en) | 2020-01-29 | 2022-09-01 | Univ Illes Balears | alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| KR20230016658A (ko) | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of their use |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| KR20230152016A (ko) | 2021-03-04 | 2023-11-02 | 얀센 파마슈티카 엔브이 | Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282B (zh) | 2021-05-10 | 2026-08-11 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
-
2019
- 2019-07-19 MA MA053172A patent/MA53172A/fr unknown
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/pt unknown
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-19 UA UAA202100695A patent/UA128558C2/uk unknown
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/ko not_active Withdrawn
- 2019-07-19 CR CR20210022A patent/CR20210022A/es unknown
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en not_active Abandoned
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en not_active Ceased
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/zh active Pending
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/ja active Active
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/es unknown
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/es unknown
- 2019-07-22 TW TW108125886A patent/TWI825134B/zh not_active IP Right Cessation
- 2019-07-22 AR ARP190102055A patent/AR115822A1/es not_active Application Discontinuation
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US12234245B2/en active Active
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/es unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/es unknown
-
2024
- 2024-12-19 US US18/988,433 patent/US20250115618A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210253596A1 (en) | 2021-08-19 |
| AU2019306658A1 (en) | 2021-01-07 |
| CR20210022A (es) | 2021-02-18 |
| SG11202013062VA (en) | 2021-02-25 |
| JP2021532101A (ja) | 2021-11-25 |
| US20250115618A1 (en) | 2025-04-10 |
| WO2020018975A1 (en) | 2020-01-23 |
| MA53172A (fr) | 2021-05-26 |
| CO2021001530A2 (es) | 2021-03-08 |
| PH12021500005A1 (en) | 2021-09-13 |
| KR20210034596A (ko) | 2021-03-30 |
| CN112513048A (zh) | 2021-03-16 |
| JP7320595B2 (ja) | 2023-08-03 |
| US12234245B2 (en) | 2025-02-25 |
| TWI825134B (zh) | 2023-12-11 |
| EP3823974A1 (en) | 2021-05-26 |
| IL279256A (en) | 2021-01-31 |
| UA128558C2 (uk) | 2024-08-14 |
| MX2021000780A (es) | 2021-03-31 |
| BR112021001044A2 (pt) | 2021-04-13 |
| AR115822A1 (es) | 2021-03-03 |
| TW202016078A (zh) | 2020-05-01 |
| PE20211811A1 (es) | 2021-09-14 |
| CA3105521A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001530A2 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| CL2021000152A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 | |
| CO2019009036A2 (es) | Compuestos químicos como inhibidores de la actividad de la interleuquina-1 | |
| ECSP22012826A (es) | Inhibidores de parp1 | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
| MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
| MX2019011825A (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad de c5a. | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2016007410A (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| CL2017002765A1 (es) | El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc). | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| CL2019001397A1 (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
| CL2015002113A1 (es) | Compuestos de azetidinloxifenilpirrolidina | |
| PE20240246A1 (es) | Compuestos de sulfonimidamida y usos de los mismos | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
| CL2019000572A1 (es) | Compuesto de imida y uso del mismo. |